hrp0095p1-400 | Thyroid | ESPE2022

Total thyroidectomies for endocrinologic indication: Experience in a third level hospital

Belen Ariza-Jimenez Ana , Antonio Ariza-Jimenez Jose

Background: To evaluate the efficacy of thyroidectomy, it is necessary to know its complications; however, there is a great discrepancy in the literature regarding its incidence. A greater surgical aggressiveness achieves better control of the disease, but may be accompanied by more complications. Hypocalcemia is the most frequent potential complication after thyroidectomy, but its persistence can lead to serious systemic effects. The objective of this study i...

hrp0095p2-187 | Growth and Syndromes | ESPE2022

Combination Down / Klinefelter syndrome - a Clinical Case

Koleva Reni , Popov Borislav , Nadegda Dimitrova , Ana Grigorova , Valeria Petrova

Introduction: The combination Down/Klinefelter syndrome was first described in 1959 by Ford. Its frequency is 0.4-0.9 / 10,000 newborn boys.Case presentation: A boy aged 5 y 4 m, born from a 2nd high-risk pregnancy (mother aged 44 with 1st pregnancy resulting in spontaneous abortion at 12 gestational weeks and with twice-established anemic syndrome) with (+) biochemical screening for Down syndrome. Birth was given via pl...

hrp0095p2-256 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2022

Case report: Roumanian baby with cytochrome P450 oxidoreductase deficiency

Simona Fica , Luminita Cima , Ana Zubaci , Raluca Oprescu

Background: POR deficiency is a rare form of congenital adrenal hyperplasia, transmitted in an autosomal recessive trait, that is characterized by ambiguous genitalia, impaired steroidogenesis and skeletal malformations similar to those of Antley-Bixler syndrome. It is caused by mutations in the P450 oxidoreductase gene (POR), an electron donor for all microsomal P450 enzymes including the three steroidogenic enzymes P450c 17 (17 alfa-hidroxylase /17,20 lyase)...

hrp0092fc13.3 | Adrenals and HP Axis | ESPE2019

YAP1-HIPPO Pathway as a Novel Prognostic Marker and Therapeutic Target for Pediatric Patients with Adrenocortical Tumors (ACT)

More Candy Bellido , Bueno Ana Carolina , Castro Margaret , Antonini Sonir

Background: There is no effective adjuvant therapy for patients with advanced ACT. YAP1, a HIPPO pathway effector, interacts with Wtn\beta-catenin pathway and plays a crucial role in the maintenance of postnatal adrenal cortex and regulates cell proliferation and apoptosis in several tissues. We recently showed that overexpression of YAP1 associates with worse prognosis in our cohort of pediatric ACT (pACT).Aim: To analy...

hrp0089p1-p020 | Adrenals and HPA Axis P1 | ESPE2018

High DHEAS (HD) in Girls Determines Earlier Pubertal Maturation and Mild Hyperandrogenism throughout Pubertal Development

Pereira Ana , Merino Paulina , Iniguez German , Corvalan Camila , Mericq Veronica

Background: Premature adrenarche (PA),characterized by high concentrations of DHEAS,has been considered a benign condition until recently,where associations to increased metabolic risk and PCOS have arisen,which may depend on ethnic background and infancy weight gain.Objective and hypotheses: To determine whether PA in girls determines:i)a different timing of pubertal events, and ii)a different pattern of Ovarian morphology/hormones and adrenal hormones....

hrp0086p2-p53 | Adrenal P2 | ESPE2016

Final Height in Congenital Adrenal Hyperplasia: A Retrospective Study

Martins Mariana , Reis-Melo Ana , Espada Filipa , Fonseca Marcelo

Background: A compromised final height (FH) is a concern in patients diagnosed with congenital adrenal hyperplasia (CAH). The lack of achievement of the genetic target height (TH) can be attributed to treatment with high doses of corticosteroids and high levels of adrenal androgens. Despite the emergence of new therapeutic modalities such as the use of anti-androgens and growth hormone it has been shown that a favorable FH can be achieved with careful use of corticosteroids.</...

hrp0084p2-546 | Puberty | ESPE2015

Gynecomastia with Precocious Onset in Peutz-Jeghers Syndrome: Managing the Aromatase Overexpression

Simoes-Pereira Joana , Marques Ana Filipa , Limbert Catarina , Lopes Lurdes

Background: Testicular tumours are an unusual cause of prepubertal gynecomastia. However, in boys with Peutz-Jeghers Syndrome (PJS), a rare autosomal dominant disorder caused by mutation in LKB1/STK11 gene, is mandatory to exclude this etiology, given the well-known association between PJS and Large-Cell Calcyfing Sertoli-Cell Tumor (LCCSCT). This mutation promotes aromatase overexpression in neoplastic Sertoli-cells, leading to gynecomastia.Case present...

hrp0094p2-3 | Adrenals and HPA Axis | ESPE2021

Endocrine-disrupting chemicals: an often-forgotten etiology of endocrinological disturbances

Lemos Ana Pereira , Duarte Mariana , Galhardo Julia , Lopes Lurdes ,

Background: Endocrine disruptors (ED) are chemicals that can mimic hormones and interfere with their receptors, causing endocrinological abnormalities.Clinical report: We present the case of a previously healthy, melanodermic, two-year-old female, who had a three-month evolution of clitoromegaly and generalized hypertrichosis. Endocrine blood work showed suppressed serum androgens suggesting steroid exogenous contact. Karyotype, bone age...

hrp0094p2-339 | Multisystem endocrine disorders | ESPE2021

Three generations of MEN-1: the importance of family screening

Duarte Mariana , Pereira Lemos Ana , Galhardo Julia , Lopes Lurdes ,

Background: Multiple Endocrine Neoplasia type 1 (MEN-1) is a rare and underdiagnosed syndrome caused by inactivating mutations of the tumor suppressor gene MEN-1 that predisposes to multiple tumors classically situated in the anterior Pituitary, Parathyroid, and Pancreas. The mutation is transmitted in an autosomal dominant way, and for this reason, the screening of all first-degree relatives is mandatory afte...

hrp0097rfc5.6 | Diabetes and insulin 1 | ESPE2023

Do females with Type 1 Diabetes have puberty earlier?

Cordero Pearson Andrea , Lucía Gomez Gila Ana , Navarro Moreno Constanza

Background: In the past, the majority of the pacients with Type 1 Diabetes (DM1) had late puberty due to hipogonadotropic hipogonadism as a result of insulin deficiency. However, the use of intensive insulin therapy nowadays, results in higher BMI what can lead to an earlier puberty. Insulin administered subcutaneously is not processed by the liver, which implies increased exposure to this hormone in the ovary leading to greater activation of theca and granulo...